Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Candel Therapeutics (CADL) has provided an update.
Candel Therapeutics, Inc. recently received Orphan Drug Designation from the FDA for their CAN-2409 drug, aimed at treating pancreatic cancer. This special status could provide developmental benefits and market exclusivity, potentially making it a noteworthy consideration for investors tracking advancements in cancer therapies and biotech sector opportunities.
For detailed information about CADL stock, go to TipRanks’ Stock Analysis page.